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Cord blood unit (CBU) transplantations to patients mismatched for only 1 HLA antigen, which is identical to
the CBU noninherited maternal antigen (NIMA), are designated as having a 6/6 “virtual” NIMA-matched
phenotype and have a prognosis similar to 6/6 inherited HLA-matched CBUs. Such virtual HLA phenotypes
of CBUs can be created by replacing the inherited alleles with 1 or more NIMAs. Phenotypes of Dutch patients
(n ¼ 2020) were matched against the inherited and virtual HLA phenotypes of the National Cord Blood
Program CBU ﬁle (with known NIMA, n ¼ 6827). Inherited 6/6 matches were found for 11% of the patients.
Including virtual phenotypes resulted in, overall, 19-fold more different phenotypes than were inherited,
conferring 6/6 virtual matches for an additional 20% of the patients, whereas another 17% might beneﬁt from
CBUs with a 4/6 HLA match and 1 NIMA match (4/6 þ 1NIMA or 5/6 virtual match). The elucidation of donors’
maternal HLA phenotypes can provide signiﬁcant numbers of 6/6 and 5/6 virtually matched CBUs to patients
and is potentially cost effective.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The immune system of the 4-month-old human fetus is
already able to produce cytotoxic T cells speciﬁc for NIMA
HLA-restricted minor histocompatibility antigens, controlled
by regulatory T cells. These cytotoxic T cells are detectable in
fetal blood, cord blood, and adult peripheral blood [1-3].
However, current cord blood unit (CBU) selection for he-
matopoietic stem cell transplantation (HSCT) overlooks the
immunological consequences of fetal exposure of the CBU
donor to maternal cells [4]. It just chooses the CBU with
highest total nucleated cell (TNC) dose among the best HLA-
matched donor available (4/6 or better HLA-A, -B “split,” and
-DRB1 “high-resolution” levels). We recently showed, in a
retrospective study, that patients with CBU transplantations
from single HLA antigenemismatched/NIMA-matched do-
nors and even from those with 2 HLA antigen mismatches
and 1 NIMAmatch (5/6 virtual match), have signiﬁcantly lessdgments on page 1795.
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ty for Blood and Marrow Transplantation.transplantation-related mortality (TRM), associated with
improved neutrophil recovery and possibly (P¼ .07), reduced
incidence of relapse [5]. Lower TRM and improved survival
were veriﬁed, independently, by a Eurocord-Center for In-
ternational Blood andMarrow Transplant Research study [6].
In general, CBUs possess 1 NIMA at each HLA-A, -B,
and -DRB1 locus, yielding up to 26 possible “virtual pheno-
types” (Table 1). If the mother is homozygous for HLA, or HLA
identical to the CBU donor at 1 or more loci, NIMAs are fewer
and, hence, CBUs yield fewer virtual HLA phenotypes.
Cord blood (CB), as a source of hematopoietic progenitor
cells, accounts for 2.5% of theworldwide stem cell donor pool
but provides stem cell products for w 20% of all unrelated
HSCT [7]. Routine maternal HLA typing of stored CBUs could
provide patients who otherwise would receive an HLA-
mismatched CBU with a 6/6 virtualematched trans-
plantation and improve the chance of such CBUs to be
chosen. Full disclosure: the TNC has not been included as a
model variable in this study’s calculations, but that does not
interfere with the validity of our immunogenetic ﬁndings.
If 2 HLAmismatches and 1 NIMAmatch improve TRM and
neutrophil recovery, it is, a priori, unlikely that 2 HLA mis-
matches and 2 NIMA matches would not give at least a
Table 1
The Potential of Creating Virtual HLA Phenotypes
Cord blood (CB) A1, A3; B7, B44; DRB1*03:01, DRB1*15:01
Mother of the CB A1, A2; B7, B8; DRB1*01:01, DRB1*15:01 NIMA [ A2, B8, and DRB1*01:01
Combining the CB phenotype with the NIMA A2, B8 and DRB1*01:01 creates the following virtual CB phenotypes for HLA -A, B, DRB1:
One substitution Two substitutions Three substitutions
A1, A2; B7, B44; DRB1*03:01, DRB1*15:01 A1, A3; B7, B8; DRB1*01:01, DRB1*15:01 A1, A2; B7, B8; DRB1*01:01, DRB1*15:01
A2, A3; B7, B44; DRB1*03:01, DRB1*15:01 A1, A3; B7, B8; DRB1*01:01, DRB1*03:01 A1, A2; B7, B8; DRB1*01:01, DRB1*03:01
A1, A3; B8, B44; DRB1*03:01, DRB1*15:01 A1, A3; B8, B44; DRB1*01:01, DRB1*15:01 A2, A3; B7, B8; DRB1*01:01, DRB1*15:01
A1, A3; B7, B8; DRB1*03:01, DRB1*15:01 A1, A3; B8, B44; DRB1*01:01,DRB1*03:01 A2, A3; B7, B8; DRB1*01:01, DRB1*03:01
A1, A3; B7, B44; DRB1*01:01, DRB1*15:01 A1, A2; B7, B44; DRB1*01:01, DRB1*15:01 A1, A2; B8, B44; DRB1*01:01, DRB1*15:01
A1, A3; B7, B44; DRB1*01:01, DRB1*03:01 A2, A3; B7, B44; DRB1*01:01, DRB1*15:01 A1, A2; B8, B44; DRB1*01:01,DRB1*03:01
A1, A2; B7, B44; DRB1*01:01, DRB1*03:01 A2, A3; B8, B44; DRB1*01:01, DRB1*15:01
A2, A3; B7, B44; DRB1*01:01, DRB1*03:01 A2, A3; B8, B44; DRB1*01:01, DRB1*03:01
A1, A2; B7, B8; DRB1*03:01, DRB1*15:01
A1, A2; B8, B44; DRB1*03:01,DRB1*15:01
A2, A3; B7, B8; DRB1*03:01,DRB1*15:01
A2, A3; B8, B44; DRB1*03:01,DRB1*15:01
Bold text facilitates the understanding that two HLA phenotypes combined deliver 26 different HLA phenotypes.
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NIMA-matched haplo-identical sibling renal and stem cell
transplantations at least suggest that unrelated 3 HLAe
antigen mismatched CBU’s compensated by 3 NIMAmatches
could also provide improved survival [8,9]. Although pro-
spective studies with 2 and 3 HLA-mismatched CBU
compensated by 2 and 3 NIMA are thus far lacking, not
including them in the relevant calculations would give an
incomplete picture of the potential usefulness of NIMA
matching. Therefore, we present here our calculations using
these additional phenotypes, but mark the results from CBU
HSCT with 2 and 3 HLA mismatches compensated by 2 and 3
NIMA matches in ﬁgures and tables in a different manner
than those from CBUs with 1 or 2 HLA mismatches and a
single NIMA match.
MATERIALS, METHODS, AND DESIGN OF THE STUDIES
Patient and Donor Files
Our study included 1 patient ﬁle of 2020 Dutch patients, of whom 15%
had a non-Caucasian background, with the required HLA typing level,
needing unrelated stem cell transplantation between 1987 and 2009. We
used the following 4 HLA-typed CBU ﬁles: ﬁle 1, National Cord Blood Pro-
gram (NCBP) CBU ﬁle of 6827 units, whose maternal HLA phenotypes and,
hence, their NIMA, are known; ﬁle 2, a Dutch CBU ﬁle (n¼ 1592 units); ﬁle 3,
an NCBP CBU ﬁle (n ¼ 40,546 units); and ﬁle 4, the Bone Marrow Donors
Worldwide (BMDW) CBU ﬁle, limited to the units with the required level of
HLA typing (n ¼ 167,201 of 465,000 units).
HLA Typing
CBU were HLA typed at the serological split-level resolution for HLA loci
A and B and for DRB1, at allele-level resolution.
Virtual Phenotype Identiﬁcation
Table 1 provides an example. The CBU donor’s phenotype for the HLA-A
locus is -A1,-A3 and the donor’s mother’s type is HLA-A1,-A2. Adding the
NIMA HLA-A2, while ignoring the inherited paternal HLA-A3, creates the
(virtual) phenotype HLA-A1,-A2. Adding the NIMA HLA-A2 for the inherited
maternal HLA-A1 adds the (second virtual) phenotype HLA-A2,-A3. The
possible NIMA additions at HLA-B and -DRB1 and combinations of additions
at 2 and 3 HLA loci are also shown.
Simulated Virtual Cord Blood Unit Phenotype
To study the impactofCBﬁle size indifferentﬁleswithunknownNIMA,we
used themaximum likelihood algorithm of Excofﬁer and Slatkin [10] to derive
the HLA -A, -B, and -DRB1 haplotype frequencies for each CBU ﬁle and used
these to assign haplotype frequency-based simulated virtual phenotypes.
Studies
Quantifying the numerical increase of HLA phenotypes by creating virtual
phenotypes
First, we marked the different inherited phenotypes in ﬁle 4, which
includes ﬁle 1. Next, we calculated how many new virtual phenotypes werecreated by the NCBP ﬁle 1 with known NIMA. Finally, the inherited virtual
phenotypes of ﬁle 1 that were also present in ﬁle 4 were identiﬁed; the
remaining virtual phenotypes were truly “new.”
HLA-matching studies
The second study determined how many 6/6 inherited and 6/6 virtual
matches could be identiﬁed with CBU ﬁle 1, with known NIMA.
We used the BMDW CB match program algorithms to identify 6/6
inherited and 6/6 virtual matches. In our match procedure, the best
matches, ie, 6/6 inherited, were evaluated ﬁrst. The matched patient
candidates were not evaluated for lower match grades, ie, 5/6 þ 1NIMA
match, or 4/6 þ 2NIMA matches, or 3/6 þ 3NIMA matches. The CBUs
chosen for a match were not withdrawn from the donor pool because
previous studies have shown that such a double usage or “allocation
conﬂict” would occur rarely (<.5%) (internal report 10 Mar 1999 “Alloca-
tion: No problem for Cord Blood Units” by H.G.M Van der Zanden, MSc,
J.J. van Rood, PhD, M. Oudshoorn, PhD and R.F. Schipper, PhD, unpublished
report).
Inherited versus simulated virtual NIMA: number of virtual phenotypes and
matches
In the third study, the number of simulated virtual CBU 6/6 NIMA
matches was compared with the number of inherited virtual 6/6 NIMA
matches from the ﬁrst study to evaluate the numerical consistency of this
simulation procedure.
Impact of cord blood ﬁle size on the effectiveness of virtual matching
In the fourth study, the small Dutch CBU ﬁle 2 (1592 units), the larger
NCBP CBU ﬁle 3 (40,546 units), and the total BMDW CBU ﬁles 4 (167,201
units with the required level of HLA typing) were separately searched to
identify 6/6 matches for the 2020 Dutch patients. The maternal HLA phe-
notypes were disregardeddwhen knowndand the simulated virtual CBU
NIMA of donor ﬁles 2, 3, and 4 were used.
NIMA matching can provide 6/6 virtual matches for patients with rare
phenotypes
In the ﬁfth study, we investigated how often NIMA matching could
provide a 6/6 virtual HLA-matched CBU to the subset of patients with rare
HLA phenotypes.RESULTS
Quantifying the Increase of HLA Phenotypes by Creating
Virtual Phenotypes
The 167,201 CBU in BMDW ﬁle 4 provide 121,376 different
inherited HLA phenotypes, including 6376 (4%) inherited
phenotypes from donor ﬁle 1 with known NIMA (Table 2).
The virtual phenotypes of ﬁle 1 numbered 122,180 (a 19.2-
fold increase), bringing the total number of distinct pheno-
types in BMDW to 224,435, after subtraction of shared
phenotypes. The 19,121 phenotypes that occur both as
inherited phenotypes in the BMDW ﬁle 4 and among the
virtual phenotypes of ﬁle 1 illustrate the limited overlap
between inherited and virtual phenotypes and provide
Table 2
Quantifying the Increase of HLA Phenotypes by Creating Virtual Phenotypes
File 4 BMDW 1 NCBP Relations
Number of CBUs 167,201 6827
Number of different inherited
phenotypes A
121,376 6376
Number of different virtual
phenotypes B
122,180
Phenotypes in common in A
and in B
19,121
Total different phenotypes of
A and B
224,435
Figure 2. Inherited versus simulated NIMA matches. NCBP ﬁle 1 (6827 CBU).
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inherited phenotypes.
NIMA Matching Effectiveness
Figure 1 summarizes the results of matching the 2020
Dutch patients against the 6827 NIMA-typed CBUs of donor
ﬁle 1. A CBUwith a 6/6-inherited match was available for 228
or 11.3% of the 2020 patients. A 5/6-matched CBU with 1
NIMA match could be identiﬁed for 193 or 9.6% of the pa-
tients, a 4/6 CBU with 2 NIMA matches for 160 or 7.9% of the
patients, as well as 3/6-matched CBU with 3 NIMA matches
for 66 or 4.6% of the patients. Thus, of the 2020 patients,
those with virtual 6/6 matches were 419 (or 21%), which,
when added to the 228 for whom an inherited 6/6matchwas
found, totaled 647, or 32%. Besides the 5/6-inherited matches
for 622 (45%) of the other 1373 patients, there were also 348
(17%) 4/6-matched CBUs with 1 NIMA match for the residual
patients, providing a 6/6 or 5/6-inherited or virtual-matched
CBU for 1617 (80%) of the 2020 patients.
Inherited versus Simulated Virtual NIMA: Number of
Virtual phenotypes and Matches
Thenumberof patientswith inheritedor simulated virtual
matches was remarkably similar, but the simulated matches
were slightly lower for 1 and 2 NIMA matches (Figure 2).
The number of simulated virtual phenotypes in CBU ﬁle 1
was 13.8% larger (n ¼ 109,564) than the sum of inherited
virtual phenotypes (n ¼ 96,377) for single, 2, and 3 HLA
mismatches. (Table 3).
Impact of Cord Blood File Size on the Effectiveness of
Virtual Matching
File size inﬂuences the proportional increase of virtual
phenotypes obtained by substitution of 1, 2, or 3 NIMA
matches (compare ﬁle 1 multiplier factor 19.2 with
Supplementary Table S1; multiplier factor 16.2, 17.4, and 14.3
for ﬁles 2, 3, and 4, respectively). The fraction of patients who
had an inherited or a simulated virtual HLA 6/6ematchedFigure 1. Match of 2020 Dutch patients versus File 1 (6827 CBU).CBU in ﬁle 2 (n ¼ 1592) was 22.1% (13.7% NIMA), in ﬁle 3
(n ¼ 40,546), 53.2% (30.3% NIMA), and in ﬁle 4 (n ¼ 167,201),
78% (31.6% NIMA) (Figure 3). Hence, even using a CBU ﬁle as
large as 167,201 units, almost 30% of the patients would
require NIMA matching to obtain a 6/6 match. Notably, the
percentage of 6/6 matches occurring more than once
increased with ﬁle size to 68% in the largest CB ﬁle 4, which
would allow using additional criteria, for CBU selection,
eg, TNC, CD34þ cell counts/viability, colony-forming unit
counts, etc.
NIMA Matching Can Provide 6/6 Virtual Matches for
Patients with Rare phenotypes
At the time of request, an HLA 9/10 or 10/10ematched,
adult unrelated donor could not be found for 112 (5%) of
the 2020 Dutch patients. When these 112 patients were
matched against the 167,201 CBUs in ﬁle 4, an inherited HLA
6/6ematched CBU was present for 9 (8%) of these 112 pa-
tients. When matched against the same panel with simu-
lated virtual phenotypes, the cumulative number of patients
with a 6/6ematched CBU increased 5-fold to 51 (46%)
(Supplementary Table S2).
DISCUSSION
At the start of our study, the NCBP CBU ﬁle 1 was the only
broadly available ﬁle with known NIMA and the required
level of HLA typing. First, we quantiﬁed the actual increase in
virtual phenotypes using this unique data set. We knew that
the maximum number of virtual phenotypes is 26 per CBU
(Table 1), but homozygosity and sharing of HLA antigens
between mother and child diminishes that number. That
prediction was conﬁrmed and showed that the increase of
inherited virtual phenotypes of the NCBP ﬁle 1 with known
NIMA was only 19-fold (Table 2). The additional ﬁnding that
some of the new inherited virtual phenotypes occurred also
as actual inherited phenotypes in ﬁle 4 proved that at least
some of the virtual phenotypes could be useful by providing
CBUs for patients needing a HSCT.
This was further substantiated when the cohort of 2020
Dutch patients who needed stem cell transplantation [pa-
tient ﬁle] was used to estimate the effectiveness of known
CBU NIMA to increase the number of optimally matched CBU
donors. Although 11.3% of these patients had an inherited
HLA 6/6ematched CBU donor in donor ﬁle 1 (Figure 1), an
additional 69% of themwould have found either a 6/6 or 5/6
CBU with 1 or more virtual NIMA matches in ﬁle 1 with
known NIMA. It should be noted that the contribution of
NIMA matching for patients with a single mismatch and 1
Table 3
Comparison of Inherited Versus Simulated NIMA Matches in NCBP File 1 (6,827 CBU)
Number of
Inherited Matches
Number of
NIMA Matches
Number of Phenotypes 6/6 Matches
Inherited Simulated Inherited, n (%) Simulated, n (%)
5/6 1 29,383 31,919 193 (9.55) 182 (9.01)
4/6 2 44,809 51,984 160 (7.92) 141 (6.98)
3/6 3 22,185 25,661 66 (3.27) 73 (3.61)
Total 96,377 109,564 419 (20.74) 396 (19.60)
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contribution for patients with 2 mismatches and 1 NIMA
match is 17.2%. In other words, including the 2
HLAemismatched 1 NIMAematched patient group triples
the effectiveness of NIMA matching with 1 NIMA to about
25% of the patients, and this has been conﬁrmed in the
Center for International Blood and Marrow Transplant
Research study [6]. Thus, NIMA matching can substantially
improve patients’ access to a virtually 6/6 or 5/6-matched
hematopoietic graft even if one restricts the search proce-
dure to the (conﬁrmed) CBUs with 1 or 2 HLA mismatches
and 1 NIMA match.
Whether NIMA matching would become less important
with larger CB inventories was explored with current CBU
inventories (without known NIMA) by simulating the most
likely NIMA from the maximum likelihood haplotype fre-
quencies. We found with the help of ﬁle 1 with known NIMA
that the proportion of inherited 6/6 NIMA matches is very
similar to that of 6/6 simulated virtual NIMAs (Figure 2).
Although the agreement between inherited and simulated
virtual phenotypes is very close, the higher number of
simulated virtual phenotypes is possibly due to haplotypes in
strong negative linkage disequilibrium, which might rarely
or not occur as inherited phenotypes. Nevertheless, many of
the virtual NIMA phenotypes (both inherited and simulated)
disclosed potentially useful matches for patients, including
those with rare HLA types (Supplementary Table S2). This
remained true even when using larger CBU ﬁles, which,
therefore, provide more inherited HLA 6/6 matches
(Figure 3). This ﬁgure illustrates the effectiveness of NIMA
matching in yet another way: the small Dutch ﬁle 2 would, if
it includes the NIMA, be able to help the same percentage of
patients (22%) as the NCBP ﬁle 3, consisting of 40,546 CBU.
Likewise, the NCBP could provide such an inherited or
simulated virtual 6/6-matched CBU to more patients than
the complete BMDW ﬁle 4 with 167,201 products without
taking NIMA matching into account. It should be realized
that in the analysis presented in Figure 3, we have not takenFigure 3. Relationship between ﬁle size and percentage of patients with a 6/6
match.into account the potential contribution to an improved
outcome due to 4/6 HLA mismatches with a single NIMA
match (5/6 virtual matches). We had 2 reasons to do so: ﬁrst,
the 6/6 virtual NIMAematched cord blood has a substantially
better survival than these 5/6 virtual NIMAematched ones
[5], and secondly, the 6/6 virtual match using 1 or 2 NIMAs
provided already an optimal transplantation for nearly 76% of
the patients, provided the NIMA of all CBUs in ﬁle 4 are
known.
Currently, the requested HLA typing for CBUs often in-
cludes the C locus and the requested HLA resolution is also
increasing, both of which further decrease the probability of
inherited 6/6 or 8/8 HLAmatches [11]. Thus, the usefulness of
NIMA matching remains applicable and becomes indis-
pensable to meet these adjusted new search criteria. Donors’
virtual phenotypes may provide patients a choice between 6/
6 inheritedeand 6/6 virtualematched CBUs (Figure 3) and a
better opportunity to balance HLA match against other
known variables. Preliminary results suggest that both hap-
loidentical NIMA-matched sibling transplantations and
NIMA-matched unrelated CB transplantations are associated
with a reduced frequency of relapse in myeloidmalignancies,
although of only borderline signiﬁcance thus far [5,9 and J.J.
Van Rood, PhD, 2002 unpublished data related to reference
9]. If this ﬁnding is conﬁrmed, the 6/6 NIMA match might be
preferable over a 6/6 inherited matchdfor speciﬁc trans-
plantation indications.
Maternal HLA typing to identify the CBUs NIMA would
add to upfront manufacturing costs [12], although the recent
introduction of “next generation” sequenceebased HLA
typing should make this addition a minor expense increase
[13]. Access to NIMAs should increase the probability that a
maternally typed CBU may be selected for transplantation
and, hence, enhance cord blood banks sustainability.
NIMA matching also expands the advantage conferred to
CBU grafts by their lower HLA match level requirements,
because of which the 550,000 CBU in BMDW [annual report
2012] match more patients of most ethnic groups than the
over 22 million registered adult donors. Without considering
NIMA information, 1 CBU can be a successful match for any 1
of circa 10 patients, with slightly different HLA phenotypes.
In contrast to adult donors who must match 5 HLA loci (ie, 9
or 10 alleles) at high resolution, CBUs matched at 4/6 or
better (HLA-A and -B at split-level and DRB1 at high reso-
lution) may sufﬁce. Because, as shown here, NIMAs endow
each CBU with an average of 13 alternative virtual pheno-
types, 1 CBU might, in theory, provide any patient from
among up to 130 patient HLA types with a 6/6 virtual match.
Most of these “up to 130” patients would otherwise require a
distinct adult donor. Thus far, this speculative projection is
only supported by the ﬁndings (in Supplementary Table S2),
where 42 of 112 (37.5%) patients with uncommon pheno-
types found a 6/6 virtual match using NIMA substitutions.
BMDW has implemented programs that derive the do-
nor’s NIMAs from thematernal HLA phenotype and use them
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up to 3 HLA antigenemismatched CBUs [14]. The CBU NIMAs
also allow, by exclusion, the identiﬁcation of the inherited
paternal antigens of the CBU. In transplantation for acute
leukemia, a CBU that does not share at least 1 of its inherited
paternal antigens with the patient was associated with
increased incidence of relapse [15].
A limitation of this study is that, in contrast to the
conﬁrmed improvement of outcomes after 1 NIMA virtual 6/
6ematched UCB transplantation, improvement for 2 or 3
HLA antigenemismatched but NIMA-matched grafts is still
unproven [5,6]. Such studies are feasible within reasonable
time because maternal HLA typing of CBU from CB banks in,
the United Kingdom, the Netherlands, Germany, Switzerland,
Croatia, and the NMDP have recently been added to those
from the NCBP, more than doubling the total number of
inherited phenotypes by virtual ones in BMDW.
As stated earlier, low CD34þ progenitor cell dose and
other negative or frankly exclusionary factors may outweigh
this immunogenetic expectation and should be considered
before selecting a 6/6 or 5/6 virtual CBU instead of a 6/6 or 5/
6 inherited CBU.
In conclusion, including the now available NIMA match
algorithm in the standard CB match program for all patients
is currently prudent and worthwhile, as it improves the
chance for 6/6 matches that reduce patient morbidity and
mortality, increases the utility of CBUs, adds clinical ﬂexi-
bility, and makes economic sense.ACKNOWLEDGMENTS
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